Gerresheimer AG (GRRMF) fair value: what the stock is really worth
As of Sep 25, 2026: fair value of Gerresheimer AG $41.88, price $29.05, upside +44.2%, quality 33 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $19.17 – $123.18 · fair‑value band $39.95 – $44.10 · the $29.05 price screens below the $41.88 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Gerresheimer AG, together with its subsidiaries, provides medicine packaging, drug delivery devices, and solutions in Germany and internationally. The company operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies.
Show more
Gerresheimer AG, together with its subsidiaries, provides medicine packaging, drug delivery devices, and solutions in Germany and internationally. The company operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. It offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and containers, bottles, caps, closures, applicators, and accessories; development, industrialization and contract manufacturing of drug delivery programs; project and quality management; and drug delivery devices, including inhalers, injection/auto injectors, and pen injectors. The company also provides diagnostic and medical devices comprising point-of-care tests, laboratory disposables, chemical and technical bottles, diagnostic and polymer vials, dropper bottles, PET bottles, and medical products comprising lancing devices, infusion sets, and disposable systems. In addition, it offers cosmetic packaging solutions, such as moulded glass flacons and jars; tubular glass ampoules, droppers, samplers and vials; and plastic packaging products, as well as pharmaceutical, laboratory, and regulatory affairs services. The company offers its products to pharmacy chains, supermarkets, and wholesalers. It serves pharma, biotech, medical technology, diagnostics, cosmetics, glass containers, and food and beverage industries. Gerresheimer AG has strategic collaboration with Newel Health to support pharma companies in integrated digital therapies. Gerresheimer AG was founded in 1864 and is based in Düsseldorf, Germany.
Stock analysis
Gerresheimer AG (GRRMF) currently trades at $29.05, while our model-based Fair Value estimate is $41.88, implying the stock looks roughly 30.6% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $64.53 per share, and 10 of the 15 models we run sit above the $29.05 price.
Bear case: the Dividend Discount group reads lowest at $15.55, and 5 of the 15 models stay below the price. Evidence for this calculation is high.
Scenario range: $39.95 (bear) to $44.10 (bull), the price of $29.05 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Gerresheimer AG reported revenue of €2.0B in FY2024 versus €1.4B in FY2020, a compound +9.4%/yr. Reported net income was €110M in FY2024, compounding +5.5%/yr from FY2020.
Key figures
Market cap $1.1B · P/E ratio 36.8 · P/S ratio 1.98 · EPS (TTM) $0.7900 · Net margin 5.4% · Return on equity 1.8% · Return on assets (EBIT) 5.5% · Operating margin 1.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 44 out of 100 (low confidence).
What moves the price
The share trades about 43% below its 52-week high and 52% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −37% fair-value upside, at 44%, GRRMF screens cheaper than that median.
Fair Value models
Bear $39.95Fair Value $41.88Bull $44.10
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2024 figures (about 12 months old). Earnings retained since then ($0.7900 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.30/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+2.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.9%
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.6%
’13
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+2.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+2.4%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.2.4% vs 4.2%, steady
Profit margin 2019 to 2024 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.9% → 10%
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Gerresheimer AG Fair Value". https://www.fairvalue-calculator.com/stock/GRRMF
Frequently asked questions
Is Gerresheimer AG (GRRMF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $41.88 versus the last price from Sep 25, 2026 of $29.05, about +44% upside (undervalued).
What is the fair value of GRRMF?
Our model-based fair value for Gerresheimer AG is $41.88 (as of Sep 24, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $29.05.
What is the quality score of GRRMF?
Gerresheimer AG has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Gerresheimer AG (GRRMF)?
Our model-based price target is the fair value of $41.88 (as of Sep 24, 2026) from 15 valuation models. Cautious scenario $39.95, optimistic scenario $44.10. It is a calculation from audited fundamentals, not an analyst target.
What is the Gerresheimer AG stock forecast for 2026?
Our models put fair value at $41.88, about +44% upside versus the last price from Sep 25, 2026 of $29.05 (undervalued). Cautious scenario $39.95, optimistic scenario $44.10. The calculation is refreshed regularly with new filings.
What is the revenue of Gerresheimer AG (GRRMF)?
Gerresheimer AG reported trailing-twelve-month revenue of about €2.3B (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Gerresheimer AG (GRRMF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Gerresheimer AG it is $41.88 per share (as of Sep 24, 2026), against a price of $29.05. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Gerresheimer AG stock overvalued or undervalued in 2026?
As of Sep 24, 2026, GRRMF trades below its calculated fair value: price $29.05, fair value $41.88, a gap of about +44% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GRRMF?
No. The price is what the market pays today ($29.05); the fair value is what the company's own numbers justify ($41.88). For Gerresheimer AG the two are $12.83 per share apart. That gap is exactly why we show both numbers side by side.
How much is Gerresheimer AG worth?
The market values Gerresheimer AG at about $1.1B (market capitalisation, as of Sep 24, 2026). Per share that is $29.05; our models calculate a fair value of $41.88 per share.
What do the bullish and bearish scenarios say about GRRMF?
Our models span a range for Gerresheimer AG: cautious scenario $39.95, base $41.88, optimistic $44.10 per share (as of Sep 24, 2026, price $29.05). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is GRRMF from its 52-week high?
Gerresheimer AG trades at $29.05, about 43% below its 52-week high of $51.41 and 52% above the low of $19.17 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $41.88 is for.
Which stocks are comparable to Gerresheimer AG?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Gerresheimer AG stock attractive at the current price?
The data as of Sep 24, 2026: price $29.05, calculated fair value $41.88 (+44%), Quality Score 33/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of GRRMF calculated?
We run Gerresheimer AG through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $41.88, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Gerresheimer AG currently trades 31 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Gerresheimer AG (GRRMF)?
The latest price we hold is from Sep 25, 2026 and stands at $29.05. Our model-based fair value is $41.88, about +44% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Gerresheimer AG right now?
The large discount to fair value meets weak quality (33/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case ($39.95). The market is more pessimistic than our downside scenario. The models converge in a tight band ($39.95 to $44.10), unusually little disagreement for a valuation.
Where does the earnings growth of Gerresheimer AG (GRRMF) come from?
Earnings per share at Gerresheimer AG grew +3.1 % a year from 2013 to 2024. Broken into its drivers: revenue per share +3.9 %, EBIT margin −1.4 %, tax rate +0.5 %, residual (interest, one-offs) +0.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Gerresheimer AG
How large is the market capitalisation of Gerresheimer AG (GRRMF)?
The market capitalisation of Gerresheimer AG is $1.1B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of Gerresheimer AG (GRRMF)?
The price-to-earnings ratio of Gerresheimer AG is 36.8. Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What is the P/S ratio of Gerresheimer AG (GRRMF)?
The price-to-sales ratio of Gerresheimer AG is 1.98 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Gerresheimer AG (GRRMF)?
Earnings per share at Gerresheimer AG are $0.7900 (price ÷ EPS = P/E 36.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Gerresheimer AG (GRRMF)?
The net margin of Gerresheimer AG is 5.4% (fiscal year 2024). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Gerresheimer AG (GRRMF)?
The return on equity (ROE) of Gerresheimer AG is 1.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Gerresheimer AG (GRRMF)?
On an EBIT basis the return on assets of Gerresheimer AG is 5.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Gerresheimer AG (GRRMF)?
The operating margin of Gerresheimer AG is 1.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Gerresheimer AG (GRRMF)?
Revenue at Gerresheimer AG is growing +12.5% versus a year earlier (3y avg +10.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Gerresheimer AG (GRRMF)?
Earnings per share at Gerresheimer AG are growing −47.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Gerresheimer AG (GRRMF) generate?
The free cash flow of Gerresheimer AG is −€130M (fiscal year 2024). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Gerresheimer AG (GRRMF) carry?
The net debt of Gerresheimer AG is €1.1B (fiscal year 2024). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Continue in the live analysis
Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.
Broad data
Sep 24, 2026